Original Article

Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer

  1. Young Joo Lee MD1,
  2. Chang Geol Lee MD2,
  3. Byoung Chul Cho MD1,
  4. Gwi Eon Kim MD, PhD2,
  5. Hye Jin Choi MD1,
  6. Eun Chang Choi MD3,
  7. Joo Hyuk Sohn MD1,
  8. Joo-Hang Kim MD, PhD1,*

Article first published online: 1 JUL 2009

DOI: 10.1002/hed.21177

Issue

Head & Neck

Head & Neck

Volume 32, Issue 2, pages 235–243, February 2010

Additional Information

How to Cite

Lee, Y. J., Lee, C. G., Cho, B. C., Kim, G. E., Choi, H. J., Choi, E. C., Sohn, J. H. and Kim, J.-H. (2010), Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. Head & Neck, 32: 235–243. doi: 10.1002/hed.21177

Author Information

  1. 1

    Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

  2. 2

    Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea

  3. 3

    Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea

*Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Publication History

  1. Issue published online: 6 JAN 2010
  2. Article first published online: 1 JUL 2009
  3. Manuscript Accepted: 20 APR 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (160K)

Keywords:

  • head-and-neck cancer;
  • chemotherapy;
  • radiotherapy;
  • 5-fluorouracil;
  • cisplatin

Abstract

Background.

In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival. Once-weekly chemotherapeutic administration schedule may reduce severe toxicities. Thus, we investigated CRT using weekly administration of 5-FU–cisplatin in locally advanced head and neck cancer.

Methods.

In a single-arm, phase II study, CRT included radiation (70.0 Gy/35 fr) and weekly 5-FU (750 mg/m2) and cisplatin (20 mg/m2).

Results.

Thirty-two patients completed planned radiation. Thirteen (41%) achieved complete response, and 16 (50%) partial response. Twelve patients (38%) experienced acute grade 3 toxicities. Grade 3 mucositis, which was the most common toxicity, developed in 5 (16%) patients. The survival rates at 1 and 2 years were 81% and 76%, respectively. The progression-free survival rates at 1 and 2 years were 69% and 66%, respectively.

Conclusions.

We demonstrated weekly 5-FU-cisplatin with conventional radiotherapy was efficacious and feasible with high compliance rate in locally advanced head and neck cancer. © 2009 Wiley Periodicals, Inc. Head Neck, 2010

View Full Article (HTML) Get PDF (160K)